Precision BioSciences (DTIL) Stock Forecast, Price Target & Predictions
DTIL Stock Forecast
Precision BioSciences stock forecast is as follows: an average price target of $15.50 (represents a 56.25% upside from DTIL’s last price of $9.92) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
DTIL Price Target
The average price target for Precision BioSciences (DTIL) is $15.50 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $30.00 to $1.00. This represents a potential 56.25% upside from DTIL's last price of $9.92.
DTIL Analyst Ratings
According to 3 Wall Street analysts, Precision BioSciences's rating consensus is 'Buy'. The analyst rating breakdown for DTIL stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Precision BioSciences Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Apr 01, 2024 | Justin Zelin | BTIG | $30.00 | $13.56 | 121.24% | 202.42% |
| Nov 10, 2022 | - | Goldman Sachs | $1.00 | $1.38 | -27.54% | -89.92% |
The latest Precision BioSciences stock forecast, released on Apr 01, 2024 by Justin Zelin from BTIG, set a price target of $30.00, which represents a 121.24% increase from the stock price at the time of the forecast ($13.56), and a 202.42% increase from DTIL last price ($9.92).
Precision BioSciences Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $30.00 |
| Last Closing Price | $9.92 | $9.92 | $9.92 |
| Upside/Downside | -100.00% | -100.00% | 202.42% |
In the current month, the average price target of Precision BioSciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Precision BioSciences's last price of $9.92. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| May 16, 2024 | Guggenheim | Underperform | Underperform | Hold |
| May 16, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Apr 01, 2024 | BTIG | Buy | Buy | Hold |
| Jun 17, 2022 | BMO Capital | - | Outperform | Initialise |
Precision BioSciences's last stock rating was published by Guggenheim on May 16, 2024. The company gave DTIL a "Underperform" rating, the same as its previous rate.
Precision BioSciences Financial Forecast
Precision BioSciences Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $13.12M | $19.79M | $8.78M | $10.60M | $7.36M | $3.82M | $3.32M | $6.34M | $24.04M | $68.81M | $16.35M | $8.85M | $7.36M | $1.08M | $7.00M | $6.52M | $4.87M | $5.39M | $5.46M |
| Avg Forecast | $11.00M | $11.00M | $13.70M | $10.00M | $7.18M | $5.28M | $7.70M | $5.34M | $12.47M | $8.99M | $6.38M | $5.67M | $6.81M | $9.86M | $4.97M | $7.73M | $9.04M | $6.02M | $13.86M | $8.30M | $5.93M | $4.34M | $5.09M | $4.14M | $8.74M | $6.21M | $8.00M | $5.55M |
| High Forecast | $15.96M | $15.96M | $19.87M | $14.51M | $10.42M | $7.66M | $11.16M | $7.75M | $18.09M | $13.05M | $9.25M | $8.23M | $9.87M | $14.30M | $6.16M | $9.58M | $11.20M | $7.46M | $17.17M | $10.28M | $7.35M | $5.38M | $6.31M | $5.13M | $10.83M | $7.69M | $9.92M | $6.88M |
| Low Forecast | $5.61M | $5.61M | $6.99M | $5.10M | $3.66M | $2.69M | $3.92M | $2.72M | $6.36M | $4.59M | $3.25M | $2.89M | $3.47M | $5.03M | $4.13M | $6.42M | $7.50M | $4.99M | $11.50M | $6.89M | $4.92M | $3.61M | $4.22M | $3.44M | $7.25M | $5.15M | $6.64M | $4.61M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.46% | 3.10% | 1.55% | 1.56% | 0.75% | 0.77% | 0.43% | 0.70% | 3.99% | 4.96% | 1.97% | 1.49% | 1.69% | 0.21% | 1.69% | 0.75% | 0.78% | 0.67% | 0.98% |
Precision BioSciences's average Quarter revenue forecast for Dec 23 based on 2 analysts is $12.47M, with a low forecast of $6.36M, and a high forecast of $18.09M. DTIL's average Quarter revenue forecast represents a -4.96% decrease compared to the company's last Quarter revenue of $13.12M (Sep 23).
Precision BioSciences EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | $-11.53M | $-11.89M | $-23.76M | $-16.01M | $-21.29M | $-28.63M | $-25.87M | $-19.74M | $-8.65M | $24.34M | $-16.22M | $-20.98M | $-23.52M | $-30.25M | $-24.45M | $-19.11M | $-19.34M | $-18.27M | $-30.66M |
| Avg Forecast | $-8.75M | $-8.75M | $-10.90M | $-7.96M | $-5.72M | $-4.20M | $-6.12M | $-4.25M | $-9.92M | $-7.15M | $-5.07M | $-4.51M | $-5.41M | $-12.25M | $-3.96M | $-29.70M | $-7.19M | $-4.79M | $-11.02M | $-21.74M | $-4.72M | $-3.46M | $-4.05M | $-24.45M | $-6.95M | $-4.94M | $-6.37M | $-85.62M |
| High Forecast | $-4.46M | $-4.46M | $-5.56M | $-4.06M | $-2.91M | $-2.14M | $-3.12M | $-2.17M | $-5.06M | $-3.65M | $-2.59M | $-2.30M | $-2.76M | $-9.80M | $-3.28M | $-23.76M | $-5.97M | $-3.97M | $-9.15M | $-17.39M | $-3.91M | $-2.87M | $-3.36M | $-19.56M | $-5.77M | $-4.10M | $-5.28M | $-68.49M |
| Low Forecast | $-12.69M | $-12.69M | $-15.81M | $-11.54M | $-8.29M | $-6.09M | $-8.88M | $-6.16M | $-14.39M | $-10.38M | $-7.36M | $-6.55M | $-7.85M | $-14.71M | $-4.90M | $-35.64M | $-8.91M | $-5.93M | $-13.66M | $-26.09M | $-5.84M | $-4.28M | $-5.02M | $-29.34M | $-8.61M | $-6.12M | $-7.89M | $-102.74M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.61% | 2.34% | 5.26% | 2.96% | 1.74% | 7.24% | 0.87% | 2.75% | 1.81% | -2.21% | 0.75% | 4.45% | 6.80% | 7.47% | 1.00% | 2.75% | 3.92% | 2.87% | 0.36% |
1 analysts predict DTIL's average Quarter EBITDA for Sep 21 to be $-4.79M, with a high of $-3.97M and a low of $-5.93M. This is -119.67% lower than Precision BioSciences's previous annual EBITDA (Jun 21) of $24.34M.
Precision BioSciences Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | - | - | - |
| Net Income | - | - | - | - | - | - | - | - | - | $-8.08M | $-11.89M | $-23.56M | $-36.49M | $-24.96M | $-32.47M | $-28.99M | $-22.34M | $-11.28M | $21.66M | $-18.69M | $-23.45M | $-26.02M | $-32.70M | $-26.84M | $-20.92M | $-20.74M | $-19.44M | $-31.78M |
| Avg Forecast | $-1.82M | $-2.31M | $-490.81K | $-2.73M | $-12.28M | $-15.69M | $-14.88M | $-16.61M | $-14.36M | $-38.39M | $-51.33M | $-47.54M | $-42.60M | $-15.98M | $-91.71M | $-32.34M | $-99.58M | $-124.51M | $-93.51M | $-25.04M | $-105.47M | $-138.30M | $-124.41M | $-26.84M | $-103.37M | $-105.88M | $-80.98M | $-88.75M |
| High Forecast | $-661.45K | $-839.50K | $-178.08K | $-992.14K | $-4.46M | $-5.69M | $-5.40M | $-6.03M | $-5.21M | $-13.93M | $-18.62M | $-17.25M | $-15.45M | $-12.78M | $-71.41M | $-25.87M | $-77.54M | $-96.96M | $-72.81M | $-20.03M | $-82.13M | $-107.70M | $-96.87M | $-21.47M | $-80.49M | $-82.44M | $-63.06M | $-71.00M |
| Low Forecast | $-2.89M | $-3.67M | $-778.36K | $-4.34M | $-19.48M | $-24.89M | $-23.59M | $-26.34M | $-22.77M | $-60.88M | $-81.39M | $-75.39M | $-67.55M | $-19.17M | $-120.20M | $-38.81M | $-130.51M | $-163.18M | $-122.55M | $-30.05M | $-138.23M | $-181.26M | $-163.05M | $-32.20M | $-135.48M | $-138.76M | $-106.14M | $-106.50M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.21% | 0.23% | 0.50% | 0.86% | 1.56% | 0.35% | 0.90% | 0.22% | 0.09% | -0.23% | 0.75% | 0.22% | 0.19% | 0.26% | 1.00% | 0.20% | 0.20% | 0.24% | 0.36% |
Precision BioSciences's average Quarter net income forecast for Sep 21 is $-124.51M, with a range of $-163.18M to $-96.96M. DTIL's average Quarter net income forecast represents a -674.96% decrease compared to the company's last Quarter net income of $21.66M (Jun 21).
Precision BioSciences SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | - | - | - |
| SG&A | - | - | - | - | - | - | - | - | - | $9.63M | $9.83M | $11.09M | $10.07M | $10.33M | $10.48M | $10.69M | $10.62M | $9.64M | $9.94M | $9.50M | $9.20M | $8.53M | $8.70M | $9.62M | $8.48M | $7.05M | $6.50M | $5.00M |
| Avg Forecast | $11.91M | $11.91M | $14.83M | $10.83M | $7.78M | $5.72M | $8.33M | $5.78M | $13.50M | $9.74M | $6.90M | $6.14M | $7.37M | $10.67M | $5.38M | $8.37M | $9.79M | $6.52M | $15.00M | $8.99M | $6.42M | $4.70M | $5.51M | $4.49M | $9.46M | $6.72M | $8.66M | $6.01M |
| High Forecast | $17.28M | $17.28M | $21.52M | $15.71M | $11.28M | $8.29M | $12.09M | $8.39M | $19.58M | $14.13M | $10.01M | $8.91M | $10.69M | $15.48M | $6.67M | $10.37M | $12.12M | $8.07M | $18.59M | $11.13M | $7.95M | $5.83M | $6.83M | $5.56M | $11.72M | $8.33M | $10.74M | $7.45M |
| Low Forecast | $6.07M | $6.07M | $7.56M | $5.52M | $3.97M | $2.91M | $4.25M | $2.95M | $6.88M | $4.96M | $3.52M | $3.13M | $3.76M | $5.44M | $4.47M | $6.95M | $8.12M | $5.41M | $12.45M | $7.46M | $5.33M | $3.90M | $4.57M | $3.72M | $7.85M | $5.58M | $7.19M | $4.99M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.99% | 1.42% | 1.80% | 1.37% | 0.97% | 1.95% | 1.28% | 1.09% | 1.48% | 0.66% | 1.06% | 1.43% | 1.81% | 1.58% | 2.14% | 0.90% | 1.05% | 0.75% | 0.83% |
Precision BioSciences's average Quarter SG&A projection for Dec 23 is $13.50M, based on 2 Wall Street analysts, with a range of $6.88M to $19.58M. The forecast indicates a 40.14% rise compared to DTIL last annual SG&A of $9.63M (Sep 23).
Precision BioSciences EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | - | - | - |
| EPS | - | - | - | - | - | - | - | - | - | $-0.07 | $-0.00 | $-0.21 | $-0.33 | $-0.23 | $-0.48 | $-0.47 | $-0.37 | $-0.19 | $0.38 | $-0.33 | $-0.45 | $-0.50 | $-0.63 | $-0.52 | $-0.41 | $-0.41 | $-0.39 | $-1.99 |
| Avg Forecast | $-0.26 | $-0.33 | $-0.07 | $-0.39 | $-1.75 | $-2.24 | $-2.12 | $-2.37 | $-2.05 | $-5.47 | $-7.32 | $-6.78 | $-6.08 | $-10.00 | $-13.08 | $-16.23 | $-14.20 | $-17.76 | $-13.34 | $-14.90 | $-15.04 | $-19.73 | $-17.74 | $-15.53 | $-14.74 | $-15.10 | $-11.55 | $-11.72 |
| High Forecast | $-0.09 | $-0.12 | $-0.03 | $-0.14 | $-0.64 | $-0.81 | $-0.77 | $-0.86 | $-0.74 | $-1.99 | $-2.66 | $-2.46 | $-2.20 | $-3.63 | $-10.19 | $-12.64 | $-11.06 | $-13.83 | $-10.38 | $-11.60 | $-11.71 | $-15.36 | $-13.82 | $-12.09 | $-11.48 | $-11.76 | $-8.99 | $-9.12 |
| Low Forecast | $-0.41 | $-0.52 | $-0.11 | $-0.62 | $-2.78 | $-3.55 | $-3.36 | $-3.76 | $-3.25 | $-8.68 | $-11.61 | $-10.75 | $-9.63 | $-15.86 | $-17.14 | $-21.28 | $-18.61 | $-23.27 | $-17.48 | $-19.52 | $-19.71 | $-25.85 | $-23.25 | $-20.35 | $-19.32 | $-19.79 | $-15.14 | $-15.35 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.01% | 0.00% | 0.03% | 0.05% | 0.02% | 0.04% | 0.03% | 0.03% | 0.01% | -0.03% | 0.02% | 0.03% | 0.03% | 0.04% | 0.03% | 0.03% | 0.03% | 0.03% | 0.17% |
According to 1 Wall Street analysts, Precision BioSciences's projected average Quarter EPS for Sep 21 is $-17.76, with a low estimate of $-23.27 and a high estimate of $-13.83. This represents a -4773.16% decrease compared to DTIL previous annual EPS of $0.38 (Jun 21).
Precision BioSciences Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PASG | Passage Bio | $0.70 | $6.00 | 757.14% | Buy |
| XFOR | X4 Pharmaceuticals | $0.65 | $3.67 | 464.62% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.22 | $7.00 | 215.32% | Buy |
| PLRX | Pliant Therapeutics | $12.87 | $40.50 | 214.69% | Buy |
| INZY | Inozyme Pharma | $4.98 | $14.00 | 181.12% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.20 | $38.80 | 173.24% | Buy |
| BDTX | Black Diamond Therapeutics | $5.40 | $14.75 | 173.15% | Buy |
| STOK | Stoke Therapeutics | $14.70 | $33.33 | 126.73% | Buy |
| TERN | Terns Pharmaceuticals | $7.81 | $12.50 | 60.05% | Buy |
| MREO | Mereo BioPharma Group | $4.32 | $6.75 | 56.25% | Buy |
| DTIL | Precision BioSciences | $9.94 | $15.50 | 55.94% | Buy |
| CYTK | Cytokinetics | $54.09 | $80.92 | 49.60% | Buy |
| DYN | Dyne Therapeutics | $33.03 | $43.88 | 32.85% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $41.84 | $51.20 | 22.37% | Buy |
| HOOK | HOOKIPA Pharma | $4.74 | $3.00 | -36.71% | Buy |
DTIL Forecast FAQ
Is Precision BioSciences a good buy?
Yes, according to 3 Wall Street analysts, Precision BioSciences (DTIL) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of DTIL's total ratings.
What is DTIL's price target?
Precision BioSciences (DTIL) average price target is $15.5 with a range of $1 to $30, implying a 56.25% from its last price of $9.92. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Precision BioSciences stock go up soon?
According to Wall Street analysts' prediction for DTIL stock, the company can go up by 56.25% (from the last price of $9.92 to the average price target of $15.5), up by 202.42% based on the highest stock price target, and down by -89.92% based on the lowest stock price target.
Can Precision BioSciences stock reach $15?
DTIL's average twelve months analyst stock price target of $15.5 supports the claim that Precision BioSciences can reach $15 in the near future.
What are Precision BioSciences's analysts' financial forecasts?
Precision BioSciences's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $25.5M (high $36.99M, low $13M), average EBITDA is $-20.285M (high $-10.343M, low $-29.427M), average net income is $-59.465M (high $-21.576M, low $-94.303M), average SG&A $27.61M (high $40.05M, low $14.08M), and average EPS is $-8.481 (high $-3.077, low $-13.45). DTIL's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $45.7M (high $66.3M, low $23.3M), average EBITDA is $-36.355M (high $-18.536M, low $-52.739M), average net income is $-7.362M (high $-2.671M, low $-11.675M), average SG&A $49.48M (high $71.77M, low $25.23M), and average EPS is $-1.05 (high $-0.381, low $-1.665).
Did the DTIL's actual financial results beat the analysts' financial forecasts?
Based on Precision BioSciences's last annual report (Dec 2023), the company's revenue was $48.73M, beating the average analysts forecast of $33.51M by 45.40%. Apple's EBITDA was $-42.527M, beating the average prediction of $-26.66M by 59.52%. The company's net income was $-61.319M, missing the average estimation of $-152M by -59.55%. Apple's SG&A was $39.09M, beating the average forecast of $36.28M by 7.73%. Lastly, the company's EPS was $-0.016, missing the average prediction of $-21.622 by -99.93%. In terms of the last quarterly report (Sep 2023), Precision BioSciences's revenue was $13.12M, beating the average analysts' forecast of $8.99M by 45.88%. The company's EBITDA was $-11.532M, beating the average prediction of $-7.155M by 61.18%. Precision BioSciences's net income was $-8.079M, missing the average estimation of $-38.389M by -78.95%. The company's SG&A was $9.63M, missing the average forecast of $9.74M by -1.07%. Lastly, the company's EPS was $-0.0701, missing the average prediction of $-5.475 by -98.72%